Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm Trial on the Addition of the DLL3xCD3 Bispecific T-cell Engager Obrixtamig (BI 764532) to Standard-of-care Platinum-based First-line Treatment of Advanced Large-cell Neuroendocrine Carcinoma of the Lung

NCT07561645 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT07561645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07561645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm Trial on the Addition of the DLL3xCD3 Bispecific T-cell Engager Obrixtamig (BI 764532) to Standard-of-care Platinum-based First-line Treatment of Advanced Large-cell Neuroendocrine Carcinoma of the Lung
Lead sponsor
Technische Universität Dresden
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
April 30, 2032
Enrollment
75 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

large cell neuroendocrine carcinoma of the lung